News & Updates

Darolutamide plus androgen-deprivation therapy (ADT), without docetaxel, improves radiological progression-free survival (rPFS) and secondary efficacy outcomes vs placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to results of the global phase III ARANOTE trial presented at ESMO 2024.

Adjuvant treatment with aspirin appears to provide some protection in patients with resected, PIK3CA-mutant stage II and III colon cancer, demonstrating a clinically significant improvement (43 percent) in disease-free survival (DFS), suggests a study presented at ESMO Congress 2024.

In patients with hepatocellular carcinoma (HCC), higher serum S-adenosylhomocysteine (SAH) concentrations may contribute to a shorter survival, regardless of the genetic variants of one-carbon metabolism key enzyme, according to a study.